Sequella, Inc. Email Format

Biotechnology ResearchUnited States2-10 Employees

Sequella, Inc. is a private, clinical-stage biotechnology company based in the United States that addresses antibiotic-resistant bacterial diseases. It advances first-in-class antibiotics with novel mechanisms of action, leveraging a proprietary library of more than 150,000 compounds to identify candidates such as SQ109, which is in Phase 2 trials for tuberculosis and Helicobacter pylori–related gastritis. The company acquired sutezolid in 2013, expanding its Phase 2 program for TB and other resistant infections, and it runs a research initiative focused on translocase-1, an essential bacterial enzyme.

Sequella targets diseases with infectious etiologies that pose global health threats, including TB, H. pylori–related duodenal ulcers and gastric carcinomas, Clostridium difficile infection, Crohn’s disease associated with Mycobacterium avium paratuberculosis, and Chagas disease caused by Trypanosoma cruzi. Positioned in the biotechnology research sector, the company pursues discovery, development, and commercialization of new antibiotics to address rising antimicrobial resistance, while operating with a relatively small team in the United States.

Sign up for free to view info

Company overview Employee directory